Up­dat­ed: Ag­i­lent throws down $725M to dou­ble man­u­fac­tur­ing ca­pac­i­ty for nu­cle­ic acids to meet API de­mand

A life sci­ence CD­MO is in­vest­ing hun­dreds of mil­lions of dol­lars in­to man­u­fac­tur­ing nu­cle­ic acids amid in­creas­ing de­mand for ac­tive phar­ma­ceu­ti­cal in­gre­di­ents, or API.

Ag­i­lent Tech­nolo­gies, which spun out of Amer­i­can tech gi­ant Hewlett Packard back in 1999, put the word out on Mon­day, say­ing that the $725 mil­lion will be used to dou­ble the com­pa­ny’s cur­rent man­u­fac­tur­ing ca­pac­i­ty for ther­a­peu­tic nu­cle­ic acids. These nu­cle­ic acids, al­so known as ther­a­peu­tic oligonu­cleotides, are DNA or RNA mol­e­cules that act as the API for cer­tain drugs that tar­get in­di­ca­tions such as can­cer or rare dis­eases.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER